Chemistry:Monalizumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | NKG2A |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies[1] and other cancers.[2][3]
Mechanism of action
Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5][6]
References
- ↑ A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
- ↑ IPH2201 studies
- ↑ First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
- ↑ AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
- ↑ "monalizumab". http://innate-pharma.com/en/product-pipeline/monalizumab-first-class-anti-nkg2a-mab-partnered-astrazeneca-and-medimmune.
- ↑ "Monalizumab: inhibiting the novel immune checkpoint NKG2A". Journal for Immunotherapy of Cancer 7 (1): 263. October 2019. doi:10.1186/s40425-019-0761-3. PMID 31623687.
 |  |
